An interventional study of Triptorelin and Cetrorelix in Infertility, sponsored by Fertility - Assisted Fertilization Center. Completed at 1 site in Brazil. Open to female participants aged Up to 35 Years. Per ClinicalTrials.gov, last updated 2012-07-13.
Sponsored by Fertility - Assisted Fertilization Center · Not applicable, Interventional, and Treatment
The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.
Inclusion criteria were as follows: women of good physical and mental health, under 37 years old, with regular menstrual cycles of 25-35 days, normal basal FSH and luteinizing hormone (LH) levels, body mass index (BMI) less than 30 kg/m2, presence of both ovaries and intact uterus, absence of polycystic ovaries, endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases.
No patient had received any hormone therapy for at least 60 days preceding the study. Eligible patients who agreed to participate were randomized in two treatment groups. Patients were allocated to a GnRH analogue treatment group according to a computer-generated randomization table.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 96 is below the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →This is the only study on the registry with Fertility - Assisted Fertilization Center as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
Drug: Triptorelin
Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
Drug: Cetrorelix
Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
Also known as: Gonapeptyl
When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
Also known as: Cetrotide
cost of treatment
Time frame: One month
Implantation and pregnancy rates
Time frame: 2 months
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.